Verrica Pharmaceuticals (VRCA) Competitors $4.09 -0.05 (-1.21%) As of 01:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VRCA vs. AVTX, SAVA, ELDN, PEPG, GNLX, IXHL, ACTU, CCCC, PYXS, and CTORShould you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Avalo Therapeutics (AVTX), Cassava Sciences (SAVA), Eledon Pharmaceuticals (ELDN), PepGen (PEPG), Genelux (GNLX), Incannex Healthcare (IXHL), Actuate Therapeutics (ACTU), C4 Therapeutics (CCCC), Pyxis Oncology (PYXS), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical products" industry. Verrica Pharmaceuticals vs. Its Competitors Avalo Therapeutics Cassava Sciences Eledon Pharmaceuticals PepGen Genelux Incannex Healthcare Actuate Therapeutics C4 Therapeutics Pyxis Oncology Citius Oncology Avalo Therapeutics (NASDAQ:AVTX) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk. Do analysts recommend AVTX or VRCA? Avalo Therapeutics currently has a consensus price target of $31.67, indicating a potential upside of 132.67%. Verrica Pharmaceuticals has a consensus price target of $60.00, indicating a potential upside of 1,372.03%. Given Verrica Pharmaceuticals' higher probable upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than Avalo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalo Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80Verrica Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is AVTX or VRCA more profitable? Verrica Pharmaceuticals' return on equity of 0.00% beat Avalo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avalo TherapeuticsN/A -48.48% -35.94% Verrica Pharmaceuticals N/A N/A -115.48% Which has more risk & volatility, AVTX or VRCA? Avalo Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Does the media prefer AVTX or VRCA? In the previous week, Verrica Pharmaceuticals had 2 more articles in the media than Avalo Therapeutics. MarketBeat recorded 4 mentions for Verrica Pharmaceuticals and 2 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 1.62 beat Verrica Pharmaceuticals' score of 0.47 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in AVTX or VRCA? 87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 0.3% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher valuation and earnings, AVTX or VRCA? Avalo Therapeutics has higher earnings, but lower revenue than Verrica Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalo Therapeutics$440K406.75-$35.13MN/AN/AVerrica Pharmaceuticals$14.70M2.62-$76.58M-$8.28-0.49 SummaryAvalo Therapeutics beats Verrica Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Verrica Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRCA vs. The Competition Export to ExcelMetricVerrica PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.53M$2.61B$6.06B$10.43BDividend YieldN/A57.77%5.73%4.78%P/E Ratio-0.4922.8285.7927.08Price / Sales2.62618.65581.41185.05Price / CashN/A25.7125.7330.17Price / Book-3.815.3212.666.66Net Income-$76.58M$32.78M$3.31B$276.03M7 Day Performance-13.09%1.09%-0.49%-1.60%1 Month Performance-14.19%9.60%8.62%5.93%1 Year Performance-69.58%-0.42%76.48%33.46% Verrica Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRCAVerrica Pharmaceuticals3.9853 of 5 stars$4.09-1.2%$60.00+1,367.0%-69.1%$38.54M$14.70M-0.4940AVTXAvalo Therapeutics3.1928 of 5 stars$14.00+4.5%$31.67+126.2%+46.2%$176.24M$440K0.0040Positive NewsSAVACassava Sciences2.4735 of 5 stars$3.57-1.7%$2.00-44.0%-85.5%$175.36MN/A-1.4030Gap UpELDNEledon Pharmaceuticals1.9596 of 5 stars$2.86+0.7%$10.00+249.7%+2.2%$170.06MN/A-2.4410Positive NewsPEPGPepGen3.4209 of 5 stars$4.96-3.3%$8.40+69.4%-46.6%$168.26MN/A-1.6830GNLXGenelux1.2453 of 5 stars$4.54+2.0%$20.33+347.9%+94.3%$168.09M$10K-5.2810Positive NewsIXHLIncannex Healthcare0.7038 of 5 stars$0.44-7.7%N/A-75.5%$167.52M$90K-0.373ACTUActuate Therapeutics1.8886 of 5 stars$7.02+0.6%$20.33+189.6%+6.0%$162.24MN/A0.0010CCCCC4 Therapeutics3.6158 of 5 stars$2.28+0.4%$8.50+272.8%-58.8%$161.56M$35.58M-1.44150PYXSPyxis Oncology2.1097 of 5 stars$2.47-3.9%$7.75+213.8%+14.4%$159.39M$16.15M-1.5460CTORCitius Oncology3.0017 of 5 stars$1.87-1.1%$6.00+220.9%+69.3%$157.84MN/A0.00N/AGap Up Related Companies and Tools Related Companies AVTX Alternatives SAVA Alternatives ELDN Alternatives PEPG Alternatives GNLX Alternatives IXHL Alternatives ACTU Alternatives CCCC Alternatives PYXS Alternatives CTOR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRCA) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
